October 27, 2025

India is not holding back! On Monday, the country took a strong step by advancing an anti-dumping investigation into imports of Ethambutol Hydrochloride from China and Thailand. Ethambutol Hydrochloride is a key ingredient used in anti-tuberculosis drugs, making it super important for India’s fight against TB. This investigation was launched last month by the Directorate General of Trade Remedies (DGTR) after India’s own drug giant Lupin Ltd raised a red flag. Lupin said imports were being dumped at very low prices, which hurts Indian producers and puts them in a tough spot. The DGTR is serious about protecting Indian industries from unfair trade. In September alone, they cracked down on 15 cases involving goods like glass fiber, steel, solar cells, and chemicals. This time, Lupin is standing tall as the domestic industry participant, while Wuhan Wuyao Pharmaceuticals Co. Ltd from China has been named among the foreign players under investigation. The DGTR statement made it clear: "There was evidence of dumping and injury, with imports undercutting domestic prices." This means Indian makers are losing out because cheaper imports flood the market. The probe covers the period from April 2024 to March 2025. If the investigation confirms damage to the Indian industry, importers could face anti-dumping duties — extra taxes aimed to level the playing field. This move is part of India’s bigger mission to fight unfair trade practices. In September, DGTR kick-started 13 new anti-dumping and countervailing cases, mostly targeting imports from China and South Korea. Looks like India means business and won’t let cheap imports kill its own industries!

Read More at Economictimes →

Tags: India, Anti-dumping, Ethambutol hydrochloride, China, Thailand, Dgtr, Lupin ltd, Pharmaceuticals,